% | $
Quotes you view appear here for quick access.

SIGA Technologies Inc. Message Board

nicehedges 6 posts  |  Last Activity: Aug 31, 2016 7:24 AM Member since: Feb 15, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Anyone still here?

    by lyvnlern Aug 29, 2016 1:57 PM
    nicehedges nicehedges Aug 31, 2016 7:24 AM Flag

    There is some discussion taking place on the desktop version (new yahoo mb). To see it on your android chrome browser you need to "request desktop site" from the menu at the top right. Yahoo continues to make this site worse as they have effectively fragmented the message boards.

  • Reply to

    The Shorties Appear to be Getting the Hint

    by twrobel1937 Jul 7, 2016 9:02 PM
    nicehedges nicehedges Jul 10, 2016 12:58 PM Flag

    Hey Musher. You're thinking of Lassa which they sold in Aug 2014 to Kineta Four as part of the "Optimization" program.
    As far as Dengue goes, they had a 5 year development grant from NIH which ended in May but was extended to April 2017. In the last 10k Siga says "We are seeking partners for our Dengue Antiviral drug candidate to support further development activity."
    The same document makes no mention of the broad spectrum antiviral but it is still listed on their website under research and discovery.

  • Reply to


    by sellhighdrinklow Jun 16, 2016 1:04 PM
    nicehedges nicehedges Jul 5, 2016 12:40 PM Flag


  • Reply to

    Volume - Increase

    by sellhighdrinklow Jun 2, 2016 3:12 PM
    nicehedges nicehedges Jun 2, 2016 4:14 PM Flag

    FWIW: 301,310 shares of today's volume were from 3 large prearranged trades that went through between .84-.85. There are no options for SIGA at this time.

  • Reply to

    For Anyone Who's Interested

    by oosetrain760 Apr 25, 2016 10:07 AM
    nicehedges nicehedges Apr 25, 2016 7:27 PM Flag

    definitely impressive. nice find.

  • NEW YORK --(BUSINESS WIRE)-- SIGA Technologies, Inc a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today that it has begun enrolling the second and final cohort of healthy subjects for the Phase III clinical study for its lead drug candidate, TPOXX (tecovirimat), for the treatment of orthopoxvirus. This Phase III study, which is wholly funded the by the Biomedical Advanced Research and Development Authority (BARDA) will be conducted at eleven approved investigative sites with a total of approximately 360 subjects.
    The initial Phase III lead cohort of 40 subjects in this trial has already completed participation without any reports of serious adverse events.
    Screening of subjects for the second Phase III cohort initiated on April 11, 2016 , and the first subject was enrolled and dosed on April 18, 2016 . Since tecovirimat is being developed under the FDA "Animal Rule," there are no efficacy endpoints in this clinical trial. This study will generate safety and pharmacokinetic data in support of the prescribing information that will be part of the New Drug Application (NDA) filing.

2.60+0.1000(+4.00%)2:22 PMEDT